GO
Loading...

Medicine

More

  • FDA approves new painkiller from OxyContin maker Wednesday, 23 Jul 2014 | 5:45 PM ET

    FDA regulators approved the drug for daily, round-the-clock pain that does not respond to other medications. The FDA notes that Targiniq can still be abused by simply swallowing the tablets, the most frequent method of painkiller abuse. The FDA has been under intense public pressure to combat the national epidemic of prescription opioid abuse.

  • Gilead beat Street estimates as Sovaldi sales soar Wednesday, 23 Jul 2014 | 4:05 PM ET
    Hepatitis-C medication Sovaldi is shown in this photo.

    Gilead Sciences delivered quarterly earnings and revenue that topped analysts' expectations on Wednesday.

  • July 23- The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer. The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia.

  • FDA approves Gilead Sciences drug for 3 cancers Wednesday, 23 Jul 2014 | 12:57 PM ET

    WASHINGTON— The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat three types of blood cancer. The FDA has approved three other drugs for the disease in the last year: Roche's Gazyva, Janssen Pharmaceutical's Imbruvica and GlaxoSmithKline's Arzerra.

  • U.S. FDA approves Gilead's blood cancer drug Zydelig Wednesday, 23 Jul 2014 | 12:05 PM ET

    July 23- The U.S. Food and Drug Administration has approved Gilead Inc's drug Zydelig to treat three types of blood cancer, the agency said on Wednesday. The FDA approved it for use in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia.

  • CNBC's Meg Tirrell speaks to Dr. George Scangos, Biogen Idec CEO, about the company's Q2 earnings surge, drug pipeline, and America's tax code. Scangos says we need a corporate tax rate that is competitive with rest of the world and a territorial tax system.

  • Faber Report: Puma Biotech surges     Wednesday, 23 Jul 2014 | 10:39 AM ET

    CNBC's David Faber reports Puma Biotechnology surges on positive results for a breast cancer drug.

  • This stock soared 300%, but options smell 'fishy' Wednesday, 23 Jul 2014 | 9:45 AM ET

    Puma Biotechnology's experimental breast cancer drug met its main goal in a late-stage trial, but the options market is sensing something funky.

  • July 22- Puma Biotechnology Inc said its experimental breast cancer drug met its main goal in a late-stage trial. Shares of the company, which doesn't have any drug in the market, tripled to $176.94 in extended trading.

  • Ackman goes after Herbalife's nutrition clubs Tuesday, 22 Jul 2014 | 4:00 PM ET

    NEW YORK— Activist investor Bill Ackman fired his latest salvo at the weight loss and nutritional supplements company Herbalife on Tuesday, alleging that one of the business models used by its distributors is evidence that the company operates as an illegal pyramid scheme.

  • HIV pills show more promise to prevent infection Tuesday, 22 Jul 2014 | 2:31 AM ET

    There is more good news about HIV treatment pills used to prevent infection in people at high risk of getting the AIDS virus: Follow-up from a landmark study that proved the drug works now shows that it does not encourage risky sex and is effective even if people skip some doses.

  • Experts: Social media can feed Munchausen by proxy Saturday, 19 Jul 2014 | 12:59 PM ET

    Lacey Spears, of Scottsville, Kentucky, has pleaded not guilty to charges of depraved murder and manslaughter in the January death of her son, Garnett-Paul Spears, whose sodium levels rose to an extremely dangerous level with no medical explanation.

  • FedEx indicted for prescription roulette     Friday, 18 Jul 2014 | 1:53 PM ET

    CNBC's Scott Cohn reports FedEx has been indicted on 15 criminal counts for helping Internet pharmacies deliver drugs to buyers in the U.S. without prescriptions.

  • 2 Fla. cases of mosquito virus contracted in US Friday, 18 Jul 2014 | 7:22 AM ET

    In both cases, they said, a person infected with the virus after visiting the Caribbean was then bitten again by an uninfected mosquito in Florida, which then transmitted the illness further.

  • Studies see new risks for cholesterol drug niacin Wednesday, 16 Jul 2014 | 5:10 PM ET

    New details from two studies reveal more side effects from niacin, a drug that hundreds of thousands of Americans take for cholesterol problems and general heart health. Some prominent doctors say the drug now seems too risky for routine use. Those details are in this week's New England Journal of Medicine.

  • 300 vials labeled influenza, dengue found at lab Wednesday, 16 Jul 2014 | 4:35 PM ET

    "The reasons why these samples went unnoticed for this long is something we're actively trying to understand," said FDA deputy director for biologics Dr.

  • ZURICH, July 16- Roche's experimental drug crenezumab failed to delay a decline in thinking and memory skills in people with Alzheimer's disease, a result likely to bolster a growing belief that drugs need to be given in earlier stages of the disease to show a benefit.

  • Roche Alzheimer's drug fails main goals in mid-stage study Wednesday, 16 Jul 2014 | 11:30 AM ET

    ZURICH, July 16- Roche said its experimental Alzheimer's drug failed to meet its main goals in a mid-stage study, a result likely to bolster the belief that drugs need to be given in earlier stages of the disease to slow patients' decline.

  • Genentech Alzheimer's drug misses goals in studies Wednesday, 16 Jul 2014 | 11:00 AM ET

    Jeffrey Cummings of the Cleveland Clinic said none of the deaths seemed due to the drug and pneumonia occurred at a rate to be expected in older people. Results were revealed Wednesday at the Alzheimer's Association International Conference in Copenhagen.

  • July 16- Pfizer Inc said a once-weekly dose of its drug, already approved for on-demand treatment of a blood clotting disorder, reduced bleeding rates in patients in a late-stage study.